Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPTCYB)

• Drug Name: Cadi-05 Drug Info
• Synonyms: Mycobacterium w; Poly-TLR agonist polyantigenic vaccine (cancer), Cadila; Poly-toll-like receptor agonist polyantigenic vaccine (cancer), Cadila

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 3	[1]

• Cross-matching ID: TTD Drug ID: DMPTCYB

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 9 (TLR9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SD-101	DMAMTGI	Hepatitis C virus infection	1E51.1	Phase 3	[3]
MGN-1703	DMCJRL1	Colorectal cancer	2B91.Z	Phase 3	[4]
IMO-2125	DM735FA	Melanoma	2C30	Phase 3	[5]
Tilsotolimod	DMGYK2N	Melanoma	2C30	Phase 3	[6]
MIS-416	DM7K4YR	Autoimmune diabetes	5A10	Phase 2	[7]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[8]
BL-7040	DMSBPJI	Inflammatory bowel disease	DD72	Phase 2	[9]
CYT003	DM4LJH8	Asthma	CA23	Phase 2	[10]
CpG-10101	DM6MUCX	Hepatitis C virus infection	1E51.1	Phase 2	[11]
JVRS-100	DMPMU38	leukaemia	2A60-2B33	Phase 2	[12]

Drug(s) Targeting Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[13]
Resatorvid	DMFMWYC	Sepsis	1G40-1G41	Phase 3	[14]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[15]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[16]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[18]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
CRX-675	DMHDSYF	Hepatitis virus infection	1E50-1E51	Phase 1	[18]
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[19]
LZ-8	DM679IY	Autoimmune diabetes	5A10	Terminated	[18]

Drug(s) Targeting Toll-like receptor 2 (TLR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MCS-18	DMX4U0B	Autoimmune diabetes	5A10	Phase 2	[20]
OPN-305	DM1IBRT	Myelodysplastic syndrome	2A37	Phase 2	[21]
MALP-2S	DMBZ68C	Pancreatic cancer	2C10	Phase 1/2	[22]
Lipoteichoic acid	DMEMRW0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[23]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[24]
S-(Dimethylarsenic)Cysteine	DMSCHL0	Discovery agent	N.A.	Investigative	[25]
CBLB-612	DMCFR8U	Radiation syndrome	NF00	Investigative	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 2 (TLR2)	TTY7ZHS	TLR2_HUMAN	Not Available	[2]
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Not Available	[2]
Toll-like receptor 9 (TLR9)	TTSHG0T	TLR9_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00810849) A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis. U.S. National Institutes of Health.
• [2] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [3] Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
• [4] Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
• [5] Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
• [6] Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
• [7] DOI: 10.1371/journal.pone.0087712
• [8] Company report (Iderapharma)
• [9] Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
• [10] CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
• [11] Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.
• [12] Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820.
• [13] Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
• [14] Clinical pipeline report, company report or official report of Takeda (2009).
• [15] Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
• [19] Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
• [20] The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31.
• [21] Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87.
• [22] Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8.
• [23] Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94.
• [24] Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
• [25] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1752).